Has Gautam Prasad, MD received payments from drug or device companies?

Yes. Drug and device makers reported $61,597 in general payments to Gautam Prasad, MD across 460 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gautam Prasad, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gautam Prasad, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gautam Prasad, MD

Radiation Oncology · Dublin, CANPI 1275755621

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 72.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $18,971 and has fallen 75.3% since, to $4,691 in 2025. Among radiation oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,597in general payments, 2019–2025

Across 460 payments — averaging $133.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novocure Inc.$45K
Accuray Incorporated$3K
Icotec Medical Inc.$3K
MIM Software Inc.$2K
AstraZeneca$1K
Johnson & Johnson$839
plus $7K from 54 others

What the payments were for

Consulting fees$4,8508%
Speaking & faculty fees$34,05055%
Travel & lodging$9,55316%
Food & beverage$13,11821%
Education$260%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novocure Inc.	82	$44,596
Accuray Incorporated	6	$2,949
Icotec Medical Inc.	21	$2,754
MIM Software Inc.	1	$1,500
AstraZeneca(2 entities)	39	$1,035
Johnson & Johnson(4 entities)	29	$839
Merck	24	$571
GE HealthCare	1	$500
Astellas Pharma US Inc	20	$392
Eisai Inc.	15	$371
Reflexion Medical, Inc.	2	$359
Takeda Pharmaceuticals U.S.A., Inc.	17	$290
Pharmacyclics LLC, An Abbvie Company	8	$261
Bioprotect Medical, Inc.	3	$252
Myriad Genetic Laboratories, Inc.	6	$228
Lilly USA, LLC	5	$226
AbbVie	9	$207
Amgen	9	$193
Pfizer	10	$193
Regeneron Healthcare Solutions, Inc.	6	$187
Novartis	7	$175
Seagen Inc.	7	$172
Genentech USA, Inc.	6	$160
Zap Surgical Systems, Inc.	1	$154
Beigene USA, Inc.	6	$128
US Oncology Corporate, Inc.	1	$126
Bayer	5	$124
Avanos Medical	5	$103
Sanofi	3	$99
Acrotech Biopharma Inc.	5	$95
Davol Inc.	3	$91
Boehringer Ingelheim	4	$90
Incyte Corporation	5	$89
Sobi, Inc	4	$87
Exelixis Inc.	2	$80
Taiho Oncology, Inc.	4	$79
Rigel Pharmaceuticals, Inc.	3	$76
Kyowa Kirin, Inc.	3	$67
Jazz Pharmaceuticals Inc.	2	$66
Deciphera Pharmaceuticals Inc.	2	$65
Pharmaessentia USA Corporation	3	$65
Dendreon Pharmaceuticals LLC	2	$64
Daiichi Sankyo Inc.	3	$64
Stemline Therapeutics Inc.	2	$58
Bard Peripheral Vascular, Inc.	1	$55
EMD Serono, Inc.	3	$52
Genmab U.S., Inc.	2	$50
Gilead	3	$48
Siemens Medical Solutions USA, Inc.	1	$47
GSK	2	$46
Myovant Sciences Inc.	2	$46
AVEO Pharmaceuticals, Inc.	2	$45
Morphosys, US Inc.	2	$44
Coherus Oncology, Inc.	2	$43
Sanofi-aventis U.S. LLC	2	$42
Apellis Pharmaceuticals, Inc.	2	$41
Servier Pharmaceuticals LLC	2	$41
Sun Pharmaceutical Industries Inc.	2	$40
Pharmacosmos Therapeutics Inc.	2	$37
Geron Corporation	1	$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,597 in reported general payments places this provider in the 95th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California →

Medicare billing

Part B allowed, 2024

$2,107,738

Medicare patients

351

Services billed

11,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	69	$729
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	11	$206
Ciprofloxacin Hcl	37	$77
Lorazepam	57	$63

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Dublin

Rakesh PatelLos Gatos$1.3M
Amir LavafPalm Springs$411K
Albert ChangLos Angeles$290K
Arya AminiDuarte$265K
Rizwan NuraniApple Valley$220K
Drew MoghanakiLos Angeles$183K
Jyoti MayadevSan Diego$170K
Percy LeeIrvine$125K
Felix FengSan Francisco$99K
Hyun KimDuarte$97K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →